Animal systems in the development of treatments for alzheimer's disease: Challenges, methods, and implications

Neurobiology of Aging

Volumn 34, Issue 1, 2013, Pages 169-183

  Sabbagh, Jonathan J ^a   Kinney, Jefferson W ^a   Cummings, Jeffrey L ^b  

^a UNIVERSITY OF NEVADA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Drug development; Review; Transgenic

Indexed keywords

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-11] ANTIBODY; AMYLOID BETA PROTEIN[1-15] ANTIBODY; AMYLOID PRECURSOR PROTEIN; BAPINEUZUMAB; BETA SECRETASE 1; BIOLOGICAL MARKER; CAD 106; CENTRAL NERVOUS SYSTEM AGENTS; CHF 5074; CHOLINESTERASE INHIBITOR; ELN 318463; ELN 475516; GRL 8234; GRL PBT 2; HOMOTAURINE; JNJ 40418677; MEMANTINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3D6; N [N (3,5 DIFLUORPHENACETYL) 1 ALANYL]PHENYLGLYCINE T BUTYL ESTER; PBT 2; PRESENILIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOID PRECURSOR PROTEIN GENE; ANIMAL BEHAVIOR; COGNITIVE DEFECT; DISEASE MARKER; DISEASE MODEL; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; GENE MUTATION; HUMAN; IMMUNOTHERAPY; MEMORY DISORDER; MENINGOENCEPHALITIS; MENTAL TASK; MUTATOR GENE; NEUROPATHOLOGY; NONHUMAN; PRESENILIN GENE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; REVIEW; TRANSGENIC ANIMAL;

ALZHEIMER DISEASE; ANIMALS; ANTIPSYCHOTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG DISCOVERY; HUMANS;

EID: 84868141734     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.02.027     Document Type: Review

References (131)

1. Adlard P.A., Bica L., White A.R., Nurjono M., Filiz G., Crouch P.J., Donnelly P.S., Cappai R., Finkelstein D.I., Bush A.I. Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease. PLoS One 2011, 6:e17669.
2. Adlard P.A., Cherny R.A., Finkelstein D.I., Gautier E., Robb E., Cortes M., Volitakis I., Liu X., Smith J.P., Perez K., Laughton K., Li Q.X., Charman S.A., Nicolazzo J.A., Wilkins S., Deleva K., Lynch T., Kok G., Ritchie C.W., Tanzi R.E., Cappai R., Masters C.L., Barnham K.J., Bush A.I. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 2008, 59:43-55.
3. Aisen P.S., Saumier D., Briand R., Laurin J., Gervais F., Tremblay P., Garceau D. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 2006, 67:1757-1763.
4. Aisen P.S., Schafer K.A., Grundman M., Pfeiffer E., Sano M., Davis K.L., Farlow M.R., Jin S., Thomas R.G., Thal L.J. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003, 289:2819-2826. Alzheimer's Disease Cooperative Study.
5. Andorfer C., Kress Y., Espinoza M., de Silva R., Tucker K.L., Barde Y.A., Duff K., Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem 2003, 86:582-590.
6. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992, 42:631-639.
7. Balducci C., Mehdawy B., Mare L., Giuliani A., Lorenzini L., Sivilia S., Giardino L., Calzà L., Lanzillotta A., Sarnico I., Pizzi M., Usiello A., Viscomi A.R., Ottonello S., Villetti G., Imbimbo B.P., Nisticò G., Forloni G., Nisticò R. The γ-secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice. J. Alzheimers Dis 2011, 24:799-816.
8. Barrow P.A., Empson R.M., Gladwell S.J., Anderson C.M., Killick R., Yu X., Jefferys J.G., Duff K. Functional phenotype in transgenic mice expressing mutant human presenilin-1. Neurobiol. Dis 2000, 7:119-126.
9. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217:408-414.
10. Basi G.S., Hemphill S., Brigham E.F., Liao A., Aubele D.L., Baker J., Barbour R., Bova M., Chen X.H., Dappen M.S., Eichenbaum T., Goldbach E., Hawkinson J., Lawler-Herbold R., Hu K., Hui T., Jagodzinski J.J., Keim P.S., Kholodenko D., Latimer L.H., Lee M., Marugg J., Mattson M.N., McCauley S., Miller J.L., Motter R., Mutter L., Neitzel M.L., Ni H., Nguyen L., Quinn K., Ruslim L., Semko C.M., Shapiro P., Smith J., Soriano F., Szoke B., Tanaka K., Tang P., Tucker J.A., Ye X.M., Yu M., Wu J., Xu Y.Z., Garofalo A.W., Sauer J.M., Konradi A.W., Ness D., Shopp G., Pleiss M.A., Freedman S.B., Schenk D. Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease. Alzheimers Res. Ther 2010, 2:36.
11. Beach T.G., Kuo Y.M., Spiegel K., Emmerling M.R., Sue L.I., Kokjohn K., Roher A.E. The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease. J. Neuropathol. Exp. Neurol 2000, 59:308-313.
12. Beck M., Bigl V., Rossner S. Guinea pigs as a nontransgenic model for APP processing in vitro and in vivo. Neurochem. Res 2003, 28:637-644.
13. Billings L.M., Green K.N., McGaugh J.L., LaFerla F.M. Learning decreases A beta*56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice. J. Neurosci 2007, 27:751-761.
14. Bittner T., Fuhrmann M., Burgold S., Jung C.K., Volbracht C., Steiner H., Mitteregger G., Kretzschmar H.A., Haass C., Herms J. Gamma-secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway. J. Neurosci 2009, 29:10405-10409.
15. Blurton-Jones M., Kitazawa M., Martinez-Coria H., Castello N.A., Müller F.J., Loring J.F., Yamasaki T.R., Poon W.W., Green K.N., LaFerla F.M. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13594-13599.
16. Boutajangout A., Quartermain D., Sigurdsson E.M. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J. Neurosci 2010, 30:16559-16566.
17. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
18. Breitner J.C., Baker L.D., Montine T.J., Meinert C.L., Lyketsos C.G., Ashe K.H., Brandt J., Craft S., Evans D.E., Green R.C., Ismail M.S., Martin B.K., Mullan M.J., Sabbagh M., Tariot P.N. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement 2011, 7:402-411. ADAPT Research Group.
19. Buerger K., Ewers M., Pirttilä T., Zinkowski R., Alafuzoff I., Teipel S.J., DeBernardis J., Kerkman D., McCulloch C., Soininen H., Hampel H. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006, 129:3035-3041.
20. Bush A.I., Pettingell W.H., Multhaup G., d Paradis M., Vonsattel J.P., Gusella J.F., Beyreuther K., Masters C.L., Tanzi R.E. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 1994, 265:1464-1467.
21. Calhoun M.E., Wiederhold K.H., Abramowski D., Phinney A.L., Probst A., Sturchler-Pierrat C., Staufenbiel M., Sommer B., Jucker M. Neuron loss in APP transgenic mice. Nature 1998, 395:755-756.
22. Chadwick W., Mitchell N., Caroll J., Zhou Y., Park S.S., Wang L., Becker K.G., Zhang Y., Lehrmann E., Wood W.H., Martin B., Maudsley S. Amitriptyline-mediated cognitive enhancement in aged 3×Tg Alzheimer's disease mice is associated with neurogenesis and neurotrophic activity. PLoS One 2011, 6:e21660.
23. Chang W.P., Huang X., Downs D., Cirrito J.R., Koelsch G., Holtzman D.M., Ghosh A.K., Tang J. Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J 2011, 25:775-784.
24. Choi J.K., Jenkins B.G., Carreras I., Kaymakcalan S., Cormier K., Kowall N.W., Dedeoglu A. Anti-inflammatory treatment in AD mice protects against neuronal pathology. Exp. Neurol 2010, 223:377-384.
25. Crawley J.N. Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res 1999, 835:18-26.
26. Crawley J.N. Behavioral phenotyping strategies for mutant mice. Neuron 2008, 57:809-818.
27. Cummings B.J., Head E., Afagh A.J., Milgram N.W., Cotman C.W. Beta-amyloid accumulation correlates with cognitive dysfunction in the aged canine. Neurobiol. Learn. Mem 1996, 66:11-23.
28. Cummings B.J., Su J.H., Cotman C.W., White R., Russell M.J. Beta-amyloid accumulation in aged canine brain: a model of early plaque formation in Alzheimer's disease. Neurobiol. Aging 1993, 14:547-560.
29. Cummings J. What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?. Biol. Psychiatry 2010, 68:876-878.
30. Cummings J.L. Alzheimer's disease clinical trials: changing the paradigm. Curr. Psychiatry Rep 2011, 13:437-442.
31. Del Valle J., Duran-Vilaregut J., Manich G., Casadesus G., Smith M.A., Camins A., Pallas M., Pelegri C., Vilaplana J. Early amyloid accumulation in the hippocampus of SAMP8 mice. J. Alzheimers Dis 2010, 19:1303-1315.
32. Delatour B., Guégan M., Volk A., Dhenain M. In vivo MRI and histological evaluation of brain atrophy in APP/PS1 transgenic mice. Neurobiol. Aging 2006, 27:835-847.
33. Dovey H.F., John V., Anderson J.P., Chen L.Z., de Saint Andrieu P., Fang L.Y., Freedman S.B., Folmer B., Goldbach E., Holsztynska E.J., Hu K.L., Johnson-Wood K.L., Kennedy S.L., Kholodenko D., Knops J.E., Latimer L.H., Lee M., Liao Z., Lieberburg I.M., Motter R.N., Mutter L.C., Nietz J., Quinn K.P., Sacchi K.L., Seubert P.A., Shopp G.M., Thorsett E.D., Tung J.S., Wu J., Yang S., Yin C.T., Schenk D.B., May P.C., Altstiel L.D., Bender M.H., Boggs L.N., Britton T.C., Clemens J.C., Czilli D.L., Dieckman-McGinty D.K., Droste J.J., Fuson K.S., Gitter B.D., Hyslop P.A., Johnstone E.M., Li W.Y., Little S.P., Mabry T.E., Miller F.D., Audia J.E. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem 2001, 76:173-181.
34. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M.N., Holcomb L., Refolo L., Zenk B., Hardy J., Younkin S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 1996, 383:710-713.
35. Duff K., Knight H., Refolo L.M., Sanders S., Yu X., Picciano M., Malester B., Hutton M., Adamson J., Goedert M., Burki K., Davies P. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol. Dis 2000, 7:87-98.
36. Dyrks T., Dyrks E., Mönning U., Urmoneit B., Turner J., Beyreuther K. Generation of beta A4 from the amyloid protein precursor and fragments thereof. FEBS Lett 1993, 335:89-93.
37. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C., Holtzman D.M. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol 2006, 59:512-519.
38. Faux N.G., Ritchie C.W., Gunn A., Rembach A., Tsatsanis A., Bedo J., Harrison J., Lannfelt L., Blennow K., Zetterberg H., Ingelsson M., Masters C.L., Tanzi R.E., Cummings J.L., Herd C.M., Bush A.I. PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J. Alzheimers Dis 2010, 20:509-516.
39. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., Jorm A., Mathers C., Menezes P.R., Rimmer E., Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117. Alzheimer's Disease International.
40. Ferrington L., Miners J.S., Palmer L.E., Bond S.M., Povey J.E., Kelly P.A., Love S., Horsburgh K.J., Kehoe P.G. Angiotensin II-inhibiting drugs have no effect on intraneuronal abeta or oligomeric abeta levels in a triple transgenic mouse model of Alzheimer's disease. Am. J. Transl. Res 2011, 3:197-208.
41. Fox L.M., William C.M., Adamowicz D.H., Pitstick R., Carlson G.A., Spires-Jones T.L., Hyman B.T. Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model. J. Neuropathol. Exp. Neurol 2011, 70:588-595.
42. Francis D.D., Zaharia M.D., Shanks N., Anisman H. Stress-induced disturbances in Morris water-maze performance: interstrain variability. Physiol. Behav 1995, 58:57-65.
43. Fu H., Li W., Lao Y., Luo J., Lee N.T., Kan K.K., Tsang H.W., Tsim K.W., Pang Y., Li Z., Chang D.C., Li M., Han Y. Bis(7)-tacrine attenuates beta amyloid-induced neuronal apoptosis by regulating L-type calcium channels. J. Neurochem 2006, 98:1400-1410.
44. Fu H., Li W., Luo J., Lee N.T., Li M., Tsim K.W., Pang Y., Youdim M.B., Han Y. Promising anti-Alzheimer's dimer bis(7)-tacrine reduces beta-amyloid generation by directly inhibiting BACE-1 activity. Biochem. Biophys. Res. Commun 2008, 366:631-636.
45. Fukumoto H., Takahashi H., Tarui N., Matsui J., Tomita T., Hirode M., Sagayama M., Maeda R., Kawamoto M., Hirai K., Terauchi J., Sakura Y., Kakihana M., Kato K., Iwatsubo T., Miyamoto M. A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J. Neurosci 2010, 30:11157-11166.
46. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373:523-527.
47. Gang B., Yue C., Han N., Xue H., Li B., Sun L., Li X., Zhao Q. Limited hippocampal neurogenesis in SAMP8 mouse model of Alzheimer's disease. Brain Res 2011, 1389:183-193.
48. Gervais F., Paquette J., Morissette C., Krzywkowski P., Yu M., Azzi M., Lacombe D., Kong X., Aman A., Laurin J., Szarek W.A., Tremblay P. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol. Aging 2007, 28:537-547.
49. Götz J., Chen F., van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001, 293:1491-1495.
50. Green R.C., Schneider L.S., Amato D.A., Beelen A.P., Wilcock G., Swabb E.A., Zavitz K.H. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009, 302:2557-2564. Tarenflurbil Phase 3 Study Group.
51. Greeve I., Kretzschmar D., Tschäpe J.A., Beyn A., Brellinger C., Schweizer M., Nitsch R.M., Reifegerste R. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J. Neurosci 2004, 24:3899-3906.
52. Hampel H., Buerger K., Zinkowski R., Teipel S.J., Goernitz A., Andreasen N., Sjoegren M., DeBernardis J., Kerkman D., Ishiguro K., Ohno H., Vanmechelen E., Vanderstichele H., McCulloch C., Moller H.J., Davies P., Blennow K. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatry 2004, 61:95-102.
53. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
54. Hawkes C., Jhamandas J.H., Kar S. Selective loss of basal forebrain cholinergic neurons by 192 IgG-saporin is associated with decreased phosphorylation of Ser glycogen synthase kinase-3beta. J. Neurochem 2005, 95:263-272.
55. Head E., Pop V., Sarsoza F., Kayed R., Beckett T.L., Studzinski C.M., Tomic J.L., Glabe C.G., Murphy M.P. Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines. J. Alzheimers Dis 2010, 20:637-646.
56. Head E., Pop V., Vasilevko V., Hill M., Saing T., Sarsoza F., Nistor M., Christie L.A., Milton S., Glabe C., Barrett E., Cribbs D. A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J. Neurosci 2008, 28:3555-3566.
57. Higuchi M. Visualization of brain amyloid and microglial activation in mouse models of Alzheimer's disease. Curr. Alzheimer Res 2009, 6:137-143.
58. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C.M., Eckman C., Younkin S., Hsiao K., Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med 1998, 4:97-100.
59. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., Nicoll J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
60. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
61. Huang X., Cuajungco M.P., Atwood C.S., Hartshorn M.A., Tyndall J.D., Hanson G.R., Stokes K.C., Leopold M., Multhaup G., Goldstein L.E., Scarpa R.C., Saunders A.J., Lim J., Moir R.D., Glabe C., Bowden E.F., Masters C.L., Fairlie D.P., Tanzi R.E., Bush A.I. Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem 1999, 274:37111-37116.
62. Imbimbo B.P., Del Giudice E., Colavito D., D'Arrigo A., Dalle Carbonare M., Villetti G., Facchinetti F., Volta R., Pietrini V., Baroc M.F., Serneels L., De Strooper B., Leon A. 1-(3', 4'-dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J. Pharmacol. Exp. Ther 2007, 323:822-830.
63. Imbimbo B.P., Giardino L., Sivilia S., Giuliani A., Gusciglio M., Pietrini V., Del Giudice E., D'Arrigo A., Leon A., Villetti G., Calzà L. CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease. J. Alzheimers Dis 2010, 20:159-173.
64. Inestrosa N.C., Alvarez A., Pérez C.A., Moreno R.D., Vicente M., Linker C., Casanueva O.I., Soto C., Garrido J. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996, 16:881-891.
65. Jack C.R., Lowe V.J., Weigand S.D., Wiste H.J., Senjem M.L., Knopman D.S., Shiung M.M., Gunter J.L., Boeve B.F., Kemp B.J., Weiner M., Petersen R.C. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132:1355-1365. Alzheimer's Disease Neuroimaging Initiative.
66. Janus C., D'Amelio S., Amitay O., Chishti M.A., Strome R., Fraser P., Carlson G.A., Roder J.C., St.George-Hyslop P., Westaway D. Spatial learning in transgenic mice expressing human presenilin 1 (PS1) transgenes. Neurobiol. Aging 2000, 21:541-549.
67. Johnstone E.M., Chaney M.O., Norris F.H., Pascual R., Little S.P. Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis. Brain Res. Mol. Brain Res 1991, 10:299-305.
68. Kalback W., Watson M.D., Kokjohn T.A., Kuo Y.M., Weiss N., Luehrs D.C., Lopez J., Brune D., Sisodia S.S., Staufenbiel M., Emmerling M., Roher A.E. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry 2002, 41:922-928.
69. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci 2001, 21:372-381.
70. Kimura R., Devi L., Ohno M. Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice. J. Neurochem 2010, 113:248-261.
71. Kinney J.W., Starosta G., Crawley J.N. Central galanin administration blocks consolidation of spatial learning. Neurobiol. Learn. Mem 2003, 80:42-54.
72. Kinney J.W., Starosta G., Holmes A., Wrenn C.C., Yang R.J., Harris A.P., Long K.C., Crawley J.N. Deficits in trace cued fear conditioning in galanin-treated rats and galanin-overexpressing transgenic mice. Learn. Mem 2002, 9:178-190.
73. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergström M., Savitcheva I., Huang G.F., Estrada S., Ausén B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Långström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol 2004, 55:306-319.
74. Klunk W.E., Lopresti B.J., Ikonomovic M.D., Lefterov I.M., Koldamova R.P., Abrahamson E.E., Debnath M.L., Holt D.P., Huang G.F., Shao L., DeKosky S.T., Price J.C., Mathis C.A. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci 2005, 25:10598-10606.
75. Koenigsknecht-Talboo J., Meyer-Luehmann M., Parsadanian M., Garcia-Alloza M., Finn M.B., Hyman B.T., Bacskai B.J., Holtzman D.M. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J. Neurosci 2008, 28:14156-14164.
76. Kukar T., Prescott S., Eriksen J.L., Holloway V., Murphy M.P., Koo E.H., Golde T.E., Nicolle M.M. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci 2007, 8:54.
77. Lannfelt L., Blennow K., Zetterberg H., Batsman S., Ames D., Harrison J., Masters C.L., Targum S., Bush A.I., Murdoch R., Wilson J., Ritchie C.W. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008, 7:779-786. PBT2-201-EURO study group.
78. Lanz T.A., Himes C.S., Pallante G., Adams L., Yamazaki S., Amore B., Merchant K.M. The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J. Pharmacol. Exp. Ther 2003, 305:864-871.
79. Lanz T.A., Karmilowicz M.J., Wood K.M., Pozdnyakov N., Du P., Piotrowski M.A., Brown T.M., Nolan C.E., Richter K.E., Finley J.E., Fei Q., Ebbinghaus C.F., Chen Y.L., Spracklin D.K., Tate B., Geoghegan K.F., Lau L.F., Auperin D.D., Schachter J.B. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J. Pharmacol. Exp. Ther 2006, 319:924-933.
80. Leanza G. Chronic elevation of amyloid precursor protein expression in the neocortex and hippocampus of rats with selective cholinergic lesions. Neurosci. Lett 1998, 257:53-56.
81. Lesné S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
82. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001, 293:1487-1491.
83. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W.L., Yen S.H., Dickson D.W., Davies P., Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet 2000, 25:402-405.
84. Li Q., Lebson L., Lee D.C., Nash K., Grimm J., Rosenthal A., Selenica M.L., Morgan D., Gordon M.N. Chronological age impacts immunotherapy and monocyte uptake independent of amyloid load. J. Neuroimmune Pharmacol 2012, 7:202-214.
85. Li W., Pi R., Chan H.H., Fu H., Lee N.T., Tsang H.W., Pu Y., Chang D.C., Li C., Luo J., Xiong K., Li Z., Xue H., Carlier P.R., Pang Y., Tsim K.W., Li M., Han Y. Novel dimeric acetylcholinesterase inhibitor bis7-tacrine, but not donepezil, prevents glutamate-induced neuronal apoptosis by blocking N-methyl-D-aspartate receptors. J. Biol. Chem 2005, 280:18179-18188.
86. Lin L., LeBlanc C.J., Deacon T.W., Isacson O. Chronic cognitive deficits and amyloid precursor protein elevation after selective immunotoxin lesions of the basal forebrain cholinergic system. Neuroreport 1998, 9:547-552.
87. Maier M., Seabrook T.J., Lazo N.D., Jiang L., Das P., Janus C., Lemere C.A. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J. Neurosci 2006, 26:4717-4728.
88. Mamikonyan G., Necula M., Mkrtichyan M., Ghochikyan A., Petrushina I., Movsesyan N., Mina E., Kiyatkin A., Glabe C.G., Cribbs D.H., Agadjanyan M.G. Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J. Biol. Chem 2007, 282:22376-22386.
89. Martinez-Coria H., Green K.N., Billings L.M., Kitazawa M., Albrecht M., Rammes G., Parsons C.G., Gupta S., Banerjee P., LaFerla F.M. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am. J. Pathol 2010, 176:870-880.
90. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
91. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 1984, 11:47-60.
92. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci 2000, 20:4050-4058.
93. Muth K., Schönmeyer R., Matura S., Haenschel C., Schröder J., Pantel J. Mild cognitive impairment in the elderly is associated with volume loss of the cholinergic basal forebrain region. Biol. Psychiatry 2010, 67:588-591.
94. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci 2006, 26:10129-10140.
95. Oddo S., Billings L., Kesslak J.P., Cribbs D.H., LaFerla F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004, 43:321-332.
96. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
97. Okura Y., Miyakoshi A., Kohyama K., Park I.K., Staufenbiel M., Matsumoto Y. Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:9619-9624.
98. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54.
99. Palop J.J., Chin J., Roberson E.D., Wang J., Thwin M.T., Bien-Ly N., Yoo J., Ho K.O., Yu G.Q., Kreitzer A., Finkbeiner S., Noebels J.L., Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007, 55:697-711.
100. Paquet D., Bhat R., Sydow A., Mandelkow E.M., Berg S., Hellberg S., Fälting J., Distel M., Köster R.W., Schmid B., Haass C. A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J. Clin. Invest 2009, 119:1382-1395.
101. Perry E.K., Blessed G., Tomlinson B.E., Perry R.H., Crow T.J., Cross A.J., Dockray G.J., Dimaline R., Arregui A. Neurochemical activities in human temporal lobe related to aging and Alzheimer-type changes. Neurobiol. Aging 1981, 2:251-256.
102. Pfeifer M., Boncristiano S., Bondolfi L., Stalder A., Deller T., Staufenbiel M., Mathews P.M., Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002, 298:1379.
103. Phillips R.G., LeDoux J.E. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav. Neurosci 1992, 106:274-285.
104. Price D.L., Martin L.J., Sisodia S.S., Wagster M.V., Koo E.H., Walker L.C., Koliatsos V.E., Cork L.C. Aged non-human primates: an animal model of age-associated neurodegenerative disease. Brain Pathol 1991, 1:287-296.
105. Roher A.E., Kuo Y.M., Potter P.E., Emmerling M.R., Durham R.A., Walker D.G., Sue L.I., Honer W.G., Beach T.G. Cortical cholinergic denervation elicits vascular A beta deposition. Ann. N. Y. Acad. Sci 2000, 903:366-373.
106. Santacruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., Guimaraes A., DeTure M., Ramsden M., McGowan E., Forster C., Yue M., Orne J., Janus C., Mariash A., Kuskowski M., Hyman B., Hutton M., Ashe K.H. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476-481.
107. Santa-María I., Hernández F., Moreno F.J., Avila J. Taurine, an inducer for tau polymerization and a weak inhibitor for amyloid-beta-peptide aggregation. Neurosci. Lett 2007, 429:91-94.
108. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
109. Schroeter S., Khan K., Barbour R., Doan M., Chen M., Guido T., Gill D., Basi G., Schenk D., Seubert P., Games D. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J. Neurosci 2008, 28:6787-6793.
110. Selkoe D.J., Bell D.S., Podlisny M.B., Price D.L., Cork L.C. Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer's disease. Science 1987, 235:873-877.
111. Seubert P., Barbour R., Khan K., Motter R., Tang P., Kholodenko D., Kling K., Schenk D., Johnson-Wood K., Schroeter S., Gill D., Jacobsen J.S., Pangalos M., Basi G., Games D. Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener. Dis 2008, 5:65-71.
112. Starkstein S.E., Mizrahi R., Power B.D. Depression in Alzheimer's disease: phenomenology, clinical correlates and treatment. Int. Rev. Psychiatry 2008, 20:382-388.
113. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Bürki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:13287-13292.
114. Takeda T., Hosokawa M., Higuchi K. Senescence-accelerated mouse (SAM): a novel murine model of accelerated senescence. J. Am. Geriatr. Soc 1991, 39:911-919.
115. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol 1991, 30:572-580.
116. Thal L.J., Ferris S.H., Kirby L., Block G.A., Lines C.R., Yuen E., Assaid C., Nessly M.L., Norman B.A., Baranak C.C., Reines S.A. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005, 30:1204-1215. Rofecoxib Protocol 078 study group.
117. Uno Y., Iwashita H., Tsukamoto T., Uchiyama N., Kawamoto T., Kori M., Nakanishi A. Efficacy of a novel, orally active GSK-3 inhibitor 6-Methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide in tau transgenic mice. Brain Res 2009, 1296:148-163.
118. Upchurch M., Wehner J.M. Differences between inbred strains of mice in Morris water maze performance. Behav. Genet 1988, 18:55-68.
119. Van Broeck B., Chen J.M., Tréton G., Desmidt M., Hopf C., Ramsden N., Karran E., Mercken M., Rowley A. Chronic treatment with a novel γ-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease. Br. J. Pharmacol 2011, 163:375-389.
120. Van Dam D., Coen K., De Deyn P.P. Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer's disease. Psychopharmacol. (Berl.) 2008, 197:37-43.
121. Van Dam D., D'Hooge R., Staufenbiel M., Van Ginneken C., Van Meir F., De Deyn P.P. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur. J. Neurosci 2003, 17:388-396.
122. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
123. Wang J., Ho L., Chen L., Zhao Z., Zhao W., Qian X., Humala N., Seror I., Bartholomew S., Rosendorff C., Pasinetti G.M. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J. Clin. Invest 2007, 117:3393-3402.
124. Wiessner C., Wiederhold K.H., Tissot A.C., Frey P., Danner S., Jacobson L.H., Jennings G.T., Lüönd R., Ortmann R., Reichwald J., Zurini M., Mir A., Bachmann M.F., Staufenbiel M. The second-generation active Aß immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J. Neurosci 2011, 31:9323-9331.
125. Wilcock D.M., Alamed J., Gottschall P.E., Grimm J., Rosenthal A., Pons J., Ronan V., Symmonds K., Gordon M.N., Morgan D. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J. Neurosci 2006, 26:5340-5346.
126. Wilcock G.K., Black S.E., Hendrix S.B., Zavitz K.H., Swabb E.A., Laughlin M.A. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 2008, 7:483-493. Tarenflurbil Phase II Study investigators.
127. Wiley R.G., Oeltmann T.N., Lappi D.A. Immunolesioning: selective destruction of neurons using immunotoxin to rat NGF receptor. Brain Res 1991, 562:149-153.
128. Wimo A., Winblad B., Jönsson L. The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement 2010, 6:98-103.
129. Wittmann C.W., Wszolek M.F., Shulman J.M., Salvaterra P.M., Lewis J., Hutton M., Feany M.B. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 2001, 293:711-714.
130. Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A.L., Citron M., Landreth G. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci 2003, 23:7504-7509.
131. Zilka N., Korenova M., Kovacech B., Iqbal K., Novak M. CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy. Acta Neuropathol 2010, 119:679-687.